Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers

被引：0
|
作者：
Payne, Susan [1 ]
Depke, Mitchell [1 ]
Yueh, Alex [1 ]
Sharick, Joseph T. [2 ]
Favreau, Peter F. [2 ]
Pasch, Cheri A. [1 ]
Clipson, Linda [1 ]
Matkowskyj, Kristina A. [1 ]
Skala, Melissa [2 ]
Deming, Dustin A. [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] Morgridge Inst Res, Madison, WI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3472
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
    Wei Yan
    Bin Zhang
    Huijun Wang
    Ran Mo
    Xingyuan Jiang
    Wen Qin
    Lin Ma
    Zhimiao Lin
    Hereditas, 158
  • [22] Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors
    Janku, F.
    Tsimberidou, A. M.
    Garrido-Laguna, I.
    Hong, D. S.
    Naing, A. M.
    Falchook, G. S.
    Fu, S.
    Luthra, R.
    Wang, X.
    Kurzrock, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 83
  • [23] PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
    McNeill, Robert S.
    Stroobant, Emily E.
    Smithberger, Erin
    Canoutas, Demitra A.
    Butler, Madison K.
    Shelton, Abigail K.
    Patel, Shrey D.
    Limas, Juanita C.
    Skinner, Kasey R.
    Bash, Ryan E.
    Schmid, Ralf S.
    Miller, C. Ryan
    PLOS ONE, 2018, 13 (07):
  • [24] Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia
    Husu, E. N.
    Roccaro, A. M.
    Anderson, K. C.
    Ghobrial, I. M.
    Leleu, X.
    Sacco, A.
    Melhem, M. R.
    Azab, A. K.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Runnels, J.
    Quang, P.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S144 - S145
  • [25] Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
    Fang, Wen-Liang
    Huang, Kuo-Hung
    Lan, Yuan-Tzu
    Lin, Chien-Hsing
    Chang, Shih-Ching
    Chen, Ming-Huang
    Chao, Yee
    Lin, Wen-Chang
    Lo, Su-Shun
    Li, Anna Fen-Yau
    Wu, Chew-Wun
    Chiou, Shih-Hwa
    Shyr, Yi-Ming
    ONCOTARGET, 2016, 7 (05) : 6201 - 6220
  • [26] PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
    Heavey, S.
    Davies, M. A.
    O'Byrne, K. J.
    Gately, K.
    LUNG CANCER, 2013, 79 : S3 - S3
  • [27] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Zhu, Yu-Fen
    Yu, Bao-Hua
    Li, Da-Li
    Ke, Hong-Lin
    Guo, Xian-Zhi
    Xiao, Xiu-Ying
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (28) : 3745 - 3751
  • [28] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
    Yu-Fen Zhu
    World Journal of Gastroenterology, 2012, (28) : 3745 - 3751
  • [29] Selective degradation of mutant PIK3CA promotes increased mutant specificity in a subset of PI3K ATP-competitive inhibitors
    Nguyen, Lan
    Edgar, Kyle
    Song, Kyung
    Schmidt, Stephen
    Schutz, Victorai
    Ishisoko, Noriko
    Torres, Eric
    Das, Akash
    Murali, Divya
    Sideris, Steve
    Wendorff, Timothy
    Saabye, Matt
    Purkey, Hans
    Sudhamsu, Jawahar
    Staben, Steven
    Hanan, Emily
    Hatzivassiliou, Georgia
    Friedman, Lori
    Endres, Nicholas F.
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 43 - 43
  • [30] Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
    Park, Ye-Lim
    Kim, Hwang-Phill
    Cho, Young-Won
    Min, Dong-Wook
    Cheon, Seul-Ki
    Lim, Yoo Joo
    Song, Sang-Hyun
    Kim, Sung Jin
    Han, Sae-Won
    Park, Kyu Joo
    Kim, Tae-You
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 389 - 401
12345